
The Registrar of the Pharmacy Council of Nigeria (PCN), Pharm. Ibrahim Babashehu Ahmed, has called for a new awakening in pharmacy practice, declaring that the revitalisation of pharmacy compounding is not just a professional ambition but a national necessity. Speaking at the maiden African Pharmacy Compounding Summit, held on Thursday, 9 October 2025, at the Providence Hotel in Ikeja GRA, Lagos, Ahmed unveiled the Council’s far-reaching vision to restore, modernise, and institutionalise compounding practices across the country.
The event, organised by the Global Alliance for Pharmacy Compounding in Africa (GAPCA), brought together major stakeholders from across Nigeria and beyond the continent of Africa, manufacturers, regulators, academics, and practitioners, in a collective effort to reimagine the role of compounding in modern healthcare. It was, in every sense, a meeting of like minds determined to redefine the pharmacist’s identity in an evolving healthcare landscape.
In his keynote address titled “Developing and Revitalising Pharmacy Compounding Practice in Nigeria: The Vision of the Council,” Ahmed described compounding as the soul of Pharmacy, a delicate fusion of science, art, innovation, and empathy. “The story of compounding is as old as Pharmacy itself,” he began, “It is where our story began, and today, it may well be the key to where our profession is going.”
He traced the historical roots of the practice, reminding the audience that before industrial manufacturing, pharmacists were therapeutic designers, crafting individualised remedies from basic raw materials. Industrialisation, while expanding access to medicines, he observed, also relegated compounding to the background, eroding one of pharmacy’s defining crafts. Yet, in a world of mass production and standardized dosages, compounding remains the lifeline for patients whose conditions demand personalized formulations — children, the elderly, oncology patients, and those with rare or chronic diseases.
Ahmed stressed that the COVID-19 pandemic was a defining moment that revalidated the relevance of compounding. When global supply chains collapsed and essential drugs became scarce, it was pharmacists, he recalled, who stepped forward to bridge the gap. “Pharmacists across Nigeria rose to the challenge, compounding sanitizers, disinfectants, and life-saving formulations when the world was in dire need,” he said. “That period reminded us that the pharmacist is not just a dispenser but an innovator, a problem-solver, and a caregiver.”
It was this reality, he explained, that inspired the PCN Governing Council at its 40th meeting in July 2020 to adopt new measures for strengthening compounding and small-scale pharmaceutical manufacturing in hospital pharmacies. The Council, in collaboration with the National Agency for Food and Drug Administration and Control (NAFDAC), initiated the accreditation of community pharmacies for extemporaneous preparations. The Federal Ministry of Health, in a circular issued in February 2021, further directed all Federal Tertiary Health Institutions to establish or reinforce hospital-based compounding and small-scale manufacturing units.
“This was not mere bureaucracy,” Ahmed emphasised. “It was a recognition of compounding as a pillar of medicines security, self-reliance, and cost-effective healthcare delivery.”
Since then, the Pharmacy Council of Nigeria has taken deliberate and strategic steps to bring this vision to life. In November 2024, it conducted a nationwide assessment of hospital compounding facilities to evaluate readiness and compliance levels. In May 2025, the PCN entered into a partnership with the United States Pharmacopoeia (USP) to develop a comprehensive concept note on revitalising pharmaceutical compounding in Nigeria. The document, he said, provided a locally driven roadmap structured around phased capacity building, infrastructure development, stakeholder engagement, and sustainability.
Building on this momentum, the PCN, in May 2025, engaged the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) to explore areas of collaboration. This engagement culminated in the submission of a memorandum to PVAC in September 2025, highlighting the revitalisation of compounding practice as one of three key areas for national partnership and investment.
“The vision of the Council is not abstract,” Ahmed declared. “It is already finding expression in our work — from issuing policy directions and engaging stakeholders to setting new regulatory benchmarks that guarantee quality, consistency, and safety in every compounded preparation.”
He explained that the Council’s vision is anchored on three key aspirations: sustainability, pharmaceutical care integration, and innovation-driven growth. Pharmacy compounding, he said, must transcend its emergency response function and evolve into a permanent, dynamic pillar of pharmaceutical care — one that empowers pharmacists as therapeutic designers and patient-centered clinicians.
Ahmed also articulated six strategic dimensions for achieving this vision: restoring pharmacy’s identity as both science and art; expanding clinical relevance through personalised medicine; driving innovation in dosage forms and formulations; fostering inter-professional and multi-sectoral collaboration; unlocking economic and professional opportunities for pharmacists; and strengthening public trust by improving patient outcomes.
While acknowledging the limitless potential of compounding, he also warned that it must be practiced with an uncompromising commitment to quality and safety. “Compounding is indispensable,” he maintained, “but it must be carried out with strict adherence to standards of quality, safety, and efficacy. Every compounded medicine must inspire confidence, not compromise it.”
Ahmed described the Council’s compounding initiative as more than a regulatory reform — as a transformative reawakening of pharmacy’s creative and scientific heritage. “This is not about nostalgia or going back to the past,” he asserted. “It is about reclaiming the best of our heritage and using it to design the future — moving pharmacy beyond transactions into transformation.”
The Registrar’s words resonated deeply with attendees, many of whom agreed that compounding represents a strategic frontier for pharmacy growth in Nigeria. By bridging clinical care and innovation, it not only addresses therapeutic gaps but also opens new avenues for research, entrepreneurship, and workforce development within the pharmaceutical value chain.
Earlier in his welcome address, Dr Ugo Ben-Nwauzor, co-founder of the Global Alliance for Pharmacy Compounding in Africa (GAPCA), reaffirmed the organisation’s mission to chart a practical path for the advancement of pharmacy compounding across the continent. He emphasised that the long-term goal was to build a sustainable compounding ecosystem in Nigeria, strengthened by collaboration and global best practices. “Our vision is to see the pharmacy compounding ecosystem in Nigeria developed in the next five to ten years,” he said. “We are already working with international partners to make this vision a reality.”
As the summit drew to a close, the prevailing sentiment among participants was clear: the future of pharmacy in Nigeria depends on reclaiming its creative roots. Compounding, they agreed, is not an outdated practice, but the very foundation upon which the pharmacist’s relevance in modern healthcare must be rebuilt.
Ahmed’s concluding words captured the spirit of that resolve. “Let us rise to this challenge,” he urged. “Let us restore Pharmacy to its full promise. Let us revitalise compounding, not as an option, but as a mandate — for the health of our patients, the growth of our profession, and the resilience of our nation.”





